Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Attention Deficit Hyperactivity Disorder Combined Clear all
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg, Placebo, Methylphenidate 0.6 mg/kg, High Intensity BMOD
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Disruptive Behavior, Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, Disruptive Behavior Disorder
Interventions
Mindful Parenting Program, MATCH BPT Program
Behavioral
Lead sponsor
New York University
Other
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced May 22, 2026, 6:01 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
ADHD, Iron-deficiency, Restless Legs Syndrome, Periodic Limb Movement Sleep Disorder
Interventions
ferrous sulfate
Dietary Supplement
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
5 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
36 Months to 131 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced May 22, 2026, 6:01 AM EDT
Active, not recruiting Phase 4 Interventional
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
Interventions
CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
ADHD
Interventions
SPD503-AM, SPD503-PM, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Mental Disorders Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorders
Interventions
Methylphenidate ER, Cyproheptadine
Drug
Lead sponsor
Douglas Sears
Individual
Eligibility
6 Years to 12 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Van Nuys, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced May 22, 2026, 6:01 AM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
ADHD - Combined Type, ADHD, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
Interventions
EYE-SYNC
Device
Lead sponsor
Sync-Think, Inc.
Industry
Eligibility
6 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Adult Attention-Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced May 22, 2026, 6:01 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, ADD, ADHD Predominantly Inattentive Type, ADHD - Combined Type, ADHD, Predominantly Hyperactive - Impulsive, Attention-Deficit Disorder in Adolescence, Attention-Deficit Hyperactivity Disorder Symptoms, Attention-Deficit Hyperactivity Disorder
Interventions
Homework Organization and Planning Skills (HOPS) Intervention, Digital Health Application (Online Platform) for Encouraging Skills Practice
Behavioral · Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
11 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced May 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Meta-Cognitive Therapy, Supportive Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced May 22, 2026, 6:01 AM EDT
Suspended Phase 3 Interventional
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Guanfacine (sustained release)
Drug
Lead sponsor
Neurology Group of Bergen County, P.A.
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
fMRI scans, Atomoxetine arm, Methylphenidate arm
Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
ADHD - Inattentive Type, ADHD - Combined Type
Interventions
OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced May 22, 2026, 6:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
Interventions
NeuroTrainer
Behavioral
Lead sponsor
NeuroTrainer
Industry
Eligibility
11 Years to 17 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Marquette, Michigan • Omaha, Nebraska • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced May 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Group-based behavior therapy, Stimulant medication therapy, Community-based psychosocial treatment
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 11 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced May 22, 2026, 6:01 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Hartford Hospital
Other
Eligibility
13 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 22, 2026, 6:01 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (Combined-subtype)
Interventions
Working memory training, Functional magnetic resonance imaging (fMRI)
Behavioral · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced May 22, 2026, 6:01 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
ADHD
Interventions
Cognitive remediation and Parent Training
Behavioral
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
7 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced May 22, 2026, 6:01 AM EDT